ALK and bone metastasis: Among them, 12 (9.4%) were over 65 years of age, 67 (52.3%) were women, 33 (25.8%) had a smoking history, 50 (39.1%) had bone metastasis at baseline, 79 (61.7%) received at least one cycle of chemotherapy before crizotinib treatment, and 19 patients (14.8%) received three or more ALK‐TKI treatments (Table 1).